Patents Examined by Peter P. Tung
-
Patent number: 6001594Abstract: The invention provides a human testin (HTES) and polynucleotides which identify and encode HTES. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HTES.Type: GrantFiled: December 31, 1997Date of Patent: December 14, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Karl J. Guegler, Neil C. Corley
-
Patent number: 5998195Abstract: A plasmid for expression of Moloney Murine Leukemia Virus-derived reverse transcriptase in E. coli cells deficient in the expression of indiginous RNAse activity, a method for purification of the recombinant enzyme, and a composition comprising a cloned and purified reverse transcriptase opimized for use in cDNA and nucleic acid amplification procedures.Type: GrantFiled: March 21, 1997Date of Patent: December 7, 1999Assignee: Gen-Probe IncorporatedInventors: Daniel Louis Kacian, Michael Garth Riggs, James Garfield Putnam
-
Patent number: 5989869Abstract: The present invention is directed to a process for improving daunorubicin and doxorubicin production by means of a recombinant microorganism in which a gene of daunorubicin metabolism involved in the glycosylation of daunorubicin to acid-sensitive, baumycin-like compounds is inactivated.Type: GrantFiled: March 6, 1997Date of Patent: November 23, 1999Assignee: Pharmacia & Upjohn S.p.A.Inventors: Silvia Filippini, Natalia Lomovskaya, Leonid Fonstein, Anna Luisa Colombo, C. Richard Hutchinson
-
Patent number: 5985638Abstract: The present invention provides a human microsomal signal peptidase subunit (HMSP) and polynucleotides which encode HMSP. The invention also provides expression vectors, host cells, agonists, antisense molecules, antibodies, or antagonists. The invention also provides methods for treating disorders associated with expression of HMSP.Type: GrantFiled: March 26, 1997Date of Patent: November 16, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5981242Abstract: The invention provides a human amino acid permease homolog (AAPH) and polynucleotides which identify and encode AAPH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of AAPH.Type: GrantFiled: February 3, 1999Date of Patent: November 9, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Henry Yue, Neil C. Corley
-
Patent number: 5972684Abstract: The invention provides a human carbonic anhydrase isoform (CAVIII) and polynucleotides which identify and encode CAVIII. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of CAVIII.Type: GrantFiled: November 25, 1997Date of Patent: October 26, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Henry Yue, Sara R. Greenwald, Neil C. Corley
-
Patent number: 5968798Abstract: The invention provides a human glutaredoxin .beta. (GRX.beta.) and polynucleotides which identify and encode GRX.beta.. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of GRX.beta..Type: GrantFiled: August 14, 1997Date of Patent: October 19, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
-
Patent number: 5962302Abstract: The invention provides a human N-acetylneuraminate lyase (HNANL) and polynucleotides which identify and encode HNANL. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HNANL.Type: GrantFiled: February 20, 1998Date of Patent: October 5, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley
-
Patent number: 5962297Abstract: Disclosed are a polypeptide having a .beta.-fructofuranosidase activity obtainable by the expression of a microbial gene, a DNA encoding the polypeptide, a transformant obtained by introducing the DNA into an appropriate host, a process for producing the polypeptide comprising culturing the transformant to produce the polypeptide and collecting the produced polypeptide from the culture, and a method for fructofuranosyl transfer comprising a step of reacting a fructofuranosyl donor with a fructofuranosyl acceptor in the presence of the polypeptide.Type: GrantFiled: June 6, 1997Date of Patent: October 5, 1999Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyujoInventors: Keiji Tsusaki, Michio Kubota, Hiroto Chaen
-
Patent number: 5959081Abstract: A substantially pure S2-6 protein (a) having a zinc binding LIM domain, (b) whose mRNA is preferentially expressed in nonproliferating or growth inhibited human diploid fibroblasts, (c) whose mRNA is overexpressed in senescent human diploid fibroblasts or human diploid fibroblasts derived from a patient with Werner Syndrome, and (c) whose mRNA expression is reduced or abolished in fetal human diploid fibroblasts, immortalized cells, cancerous cells and other highly proliferative cells.Type: GrantFiled: May 14, 1997Date of Patent: September 28, 1999Assignee: The Board of Trustees of the University of ArkansasInventor: Beata Lecka-Czernik
-
Patent number: 5942399Abstract: The invention provides a human amino acid permease homolog (AAPH) and polynucleotides which identify and encode AAPH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of AAPH.Type: GrantFiled: May 6, 1998Date of Patent: August 24, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Henry Yue, Neil C. Corley
-
Patent number: 5928925Abstract: An object of the present invention is to isolate complementary DNA coding for ornithine carbamyltransferase derived from a rice plant, necessary for development of a plant ornithine carbamyltransferase gene mutated to have phaseolotoxin resistance, and further to establish an expression system in microorganisms for simply evaluating the functions of the gene mutated to have resistance. This object is solved by a rice ornithine carbamyltransferase gene coding for a protein consisting of the amino acid sequence shown in SEQ ID NO:6 in the Sequence Listing, a plasmid vector containing the gene, and a transformant carrying the plasmid vector.Type: GrantFiled: June 5, 1998Date of Patent: July 27, 1999Assignee: Director of National Food Research Institute, Ministry of Agriculture, Forestry and FisheriesInventors: Yoshifumi Ito, Akihiro Hino, Hirohito Miura
-
Patent number: 5919686Abstract: The invention provides two human NADH dehydrogenase subunits (HNDS) and polynucleotides which identify and encode HNDS. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HNDS.Type: GrantFiled: August 8, 1997Date of Patent: July 6, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman, Karl J. Guegler, Purvi Shah
-
Patent number: 5914390Abstract: Methods are disclosed for increasing the yields of recombinant proteins. Addition of one or more protective agents, such as a sulfated compound (including heparin, heparin sulfate, sodium dodecyl sulfate, and the like), hyaluronic acid or deoxycholate, to recombinant protein production processes is disclosed. Addition of protective agents to the recombinant production process results in increased yields of recombinant proteins.Type: GrantFiled: May 12, 1997Date of Patent: June 22, 1999Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Ranga Nathan, Henryk Cudny
-
Patent number: 5876997Abstract: The invention provides a purified phytate enzyme derived from Escherichia coli B. The enzyme has a molecular weight of about 47.1 kilodaltons and has phytase activity (SEQ ID NO:2). The enzyme can be produced from native or recombinant host cells and can be used to aid in the digestion of phytate where desired. In particular, the phytase of the present invention can be used in animal feed.Type: GrantFiled: August 13, 1997Date of Patent: March 2, 1999Assignee: Diversa CorporationInventor: Keith Kretz
-
Patent number: 5869289Abstract: The present invention provides a polynucleotide which identifies and encodes a novel human galectin-8. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding human galectin-8. The invention also provides for the production and use of substantially purified human galectin-8 in pharmaceutical compositions to increase immune responses. The invention also provides for the use of antisense molecules and antibodies in pharmaceutical compositions to decrease immune response. The invention also describes diagnostic assays which utilize the polynucleotide to hybridize with the transcripts and/or genomic DNA encoding human galectin-8 and anti-human galectin-8 antibodies which specifically bind to human galectin-8.Type: GrantFiled: October 9, 1996Date of Patent: February 9, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Phillip R. Hawkins, Olga Bandman
-
Patent number: 5869309Abstract: The instant invention provides nucleic acid molecules encoding cephalosporin esterase from Rhodosporidium toruloides. In addition, the invention provides isolated cephalosporin esterase, expression vectors, host cells, and methods of producing cephalosporin esterase.Type: GrantFiled: September 17, 1997Date of Patent: February 9, 1999Assignee: Bristol-Myers Squibb Co.Inventors: Michael Politino, Sean M. Tonzi, John J. Usher, William V. Burnett, Guna Romancik
-
Patent number: 5869307Abstract: The invention provides a novel GDP-mannose 4,6-dehydratase.Type: GrantFiled: December 3, 1997Date of Patent: February 9, 1999Assignee: Genetics Institute, Inc.Inventors: Francis Sullivan, Ronald Kriz, Ravindra Kumar
-
Patent number: 5866391Abstract: The present invention relates to Aspergillus porphobilinogen synthases and isolated nucleic acid fragments comprising nucleic acid sequences encoding the porphobilinogen synthases as well as nucleic acid constructs, vectors, and recombinant host cells comprising the nucleic acid sequences. The invention also relates to methods of producing the porphobilinogen synthases.Type: GrantFiled: June 9, 1997Date of Patent: February 2, 1999Assignee: Novo Nordisk Biotech, Inc.Inventors: Aubrey Jones, Joel R. Cherry
-
Patent number: 5861294Abstract: The present invention provides an adenosine kinase protein having an identified structural formula. The identified protein or similar adenosine kinase proteins having residues as claimed and recited herein may be isolated and purified from natural sources or produced by recombinant DNA technology.Type: GrantFiled: June 7, 1995Date of Patent: January 19, 1999Assignee: Abbott LaboratoriesInventors: Marlon Daniel Cowart, Donald N. Halbert, James F. Kerwin, Jr., Teresa McNally